For the Inventor, By the Inventor

Enter assignee name

Redwood City, CA, United States of America

Pharmagenesis, Inc.

Calculating rank

USPTO Granted Patents = 25

% Expired Patents = 64.0

EPO Patents = 1

Forward Citations = 272

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

John H Musser (19 out of 113 patents)

Dongcheng Dai (11 out of 52 patents)

John M Fidler (4 out of 6 patents)

4. Hongwei Yuan (4 out of 4 patents)

5. Edwin S Lennox (4 out of 7 patents)

6. Jian Wang (2 out of 25 patents)

7. Jinhua An (2 out of 4 patents)

8. Gary Allan Strobel (2 out of 61 patents)

9. You Mao Qi (2 out of 2 patents)

10. Nathan B Pliam (2 out of 2 patents)

11. Ke Li (1 out of 33 patents)

12. Rensheng Xu (1 out of 3 patents)

13. Karen S Leu (1 out of 1 patent)

14. Glenn D Rosen (1 out of 5 patents)

15. Concepcion Martinez-Miller (1 out of 1 patent)

Core Competencies:

Triptolide Derivatives

Immunomodulators

Anticancer Agents

Prodrugs

Apoptosis Modulation

Diterpenoid Compounds

Amino Acid Derivatives

Halogenated Compounds

Immunotherapy

Xenograft Rejection

Anti-Proliferative Agents

Fungal Compounds

25 patents: Sort by Forward Citations

1. 8617906 - Identification and screening of triptolide target molecules (2013-12-31),

2. 8426616 - Triptolide lactone ring derivatives as immunomodulators and anticancer agents (2013-04-23),

3. 8268882 - Triptolide C-ring derivatives as anticancer agents and immune modulators (2012-09-18),

4. 8048914 - [object Object] (2011-11-01),

5. 7863464 - Triptolide lactone ring derivatives as immunomodulators and anticancer agents (2011-01-04),

6. 7847109 - Triptolide derivatives for modulation of apoptosis and immunosuppression (2010-12-07),

7. 7820834 - Triptolide 5,6-derivatives as immunomodulators and anticancer agents (2010-10-26),

8. 7662976 - Triptolide derivatives for modulation of apoptosis and immunosuppression (2010-02-16),

9. 7417069 - Halogenated triptolide derivatives as immunomodulators and anticancer agents (2008-08-26),

10. 7098348 - Triptolide derivatives as immunomodulators and anticancer agents (2006-08-29),

11. 7019151 - Triptolide derivatives as immunomodulators and anticancer agents (2006-03-28),

12. 6991817 - Acid-modified arabinogalactan protein composition (2006-01-31),

13. 6949510 - Uses of diterpenoid triepoxides as an anti-proliferative agent (2005-09-27),

14. 6943259 - Halogenated triptolide derivatives as immunomodulators and anticancer agents (2005-09-13),

15. 6620843 - Anticancer treatment using triptolide prodrugs (2003-09-16),

Company Overview

Pharmagenesis, Inc. is a biotechnology company based in Redwood City, California, specializing in the development of innovative therapeutic solutions. The organization focuses on advancing drug discovery and development processes, particularly in the fields of molecular biology and pharmacology. By leveraging cutting-edge research and technology, Pharmagenesis aims to address unmet medical needs and improve patient outcomes through its specialized expertise in biopharmaceuticals and targeted therapies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

25 Patents

#79 in Redwood City, CA

#3,162 in California

#13,379 in US

#25,748 in the World

Redwood City, CA, United States of America

Pharmagenesis, Inc.

Forward Citations = 272

21 inventors:

John H Musser (19 out of 113 patents)

Dongcheng Dai (11 out of 52 patents)

John M Fidler (4 out of 6 patents)

4. Hongwei Yuan (4 out of 4 patents)

5. Edwin S Lennox (4 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Pharmagenesis, Inc.. Retrieved from https://idiyas.com/company/pharmagenesis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…